anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Diffuse large B-cell lymphoma (DLBCL) is an aggressive B-cell lymphoma curable even in advanced stages. DLBCL involving the central nervous system (CNS) is more difficult to cure and fewer treatment options exist. Primary CNS lymphoma (PCNSL) refers to aggressive lymphomas confined to the CNS, and are almost always DLBCL. Standard approaches for PCNSL use high-dose methotrexate-based combinations as induction therapy and younger patients often receive dose-intensive consolidation. However, dose-intensive therapies are not suitable for all patients, and older patients have fewer effective treatment options. Patients with relapsed or chemotherapy-refractory disease have a very poor prognosis. Secondary CNS lymphoma (SCNSL) describes aggressive lymphomas involving the CNS at initial presentation or relapses within the CNS after treatment for systemic DLBCL. Isolated CNS relapse is often managed as PCNSL, but patients with synchronous involvement of DLBCL in both the periphery and the CNS pose a unique clinical challenge. Insights into the molecular circuitry of DLBCL have identified distinct genetic subtypes including cases with a predilection for CNS invasion. PCNSL and subsets of SCNSL are characterized by chronically activated B-cell receptor and NFκB signaling along with genetic evidence of immune evasion which may be exploited therapeutically. Improved mechanistic understanding of targetable pathways underpinning CNS lymphomas has led to numerous clinical trials testing targeted agent combinations and immunotherapy approaches with promising early results. Biologically rational strategies may further improve the cure rate of CNS lymphomas, either by overcoming intrinsic or acquired treatment resistance and/or by being broadly applicable to patients of all ages.
The present invention relates to a preparation technology and a production method for an integrated new formulation of an astragalus and cinnamon twig five agents decoction, wherein the raw materials of active ingredients comprise: 9 parts by weight of astragalus, 9 parts by weight of Chinese herbaceous peony, 9 parts by weight of cinnamon twig, 18 parts by weight of ginger, and 4 parts by weight of Chinese-date. The production process of the integrated new formulation comprises the following steps of: supersonic air-jet crushing, alcohol-water extraction, ultrasonic crushing extraction, water decocting concentration, supersonic spray drying, nanometer grinding, high pressure homogenization, nano particle preparation and the like. According to the invention, the advantages, such as multi-synergism, multi-target, embodied by a nano-carrier coupling technique, are focused to be taken of. After the integrated new formulation of astragalus and cinnamon twig five agents decoction is subjected to scale production, the production cost can be greatly reduced, the quality of products is greatly improved and the targeting property and the sustained and controlled release performance of the medicament are enhanced. The internal and external administration of the integrated new formulation of astragalus and cinnamon twig five agents decoction can be realized simultaneously, and can be respectively taken in four time slices according to midnight-noon ebb-flow and qi and blood flowing rule of a human body. The integrated new formulation of astragalus and cinnamon twig five agents decoction can be further prepared into films and transdermal agents which are respectively stuck to different parts of a human body according to the midnight-noon ebb-flow and qi and blood flowing rule of the human body and can be directly absorbed through skin.
Patients with hematologic malignancies are at increased risk of adverse COVID-19 outcomes; nonetheless, only sparse population-based data are available on mortality related to hematologic cancers during the pandemic. Number of deaths and age-standardized mortality rates for specific hematologic malignancies selected either as the underlying cause of death (UCOD), or mentioned in death certificates (multiple causes of death-MCOD) were extracted from the US National Center for Health Statistics, CDC WONDER Online Database. Joinpoint analysis was applied to identify changes in mortality trends from 1999 to 2021, and to estimate the annual percent change with 95% Confidence Intervals (CI) across time segments. Among the most common malignancies, chronic lymphocytic leukemia showed marked peaks in the monthly number of deaths attributed to COVID-19 during epidemic waves; acute myeloid leukemia showed the least variation, and non-Hodgkin lymphoma and multiple myeloma were characterized by an intermediate pattern. Age-standardized death rates relying solely on the UCOD did not show significant variations during pandemic years. By contrast, rates based on MCOD increased by 14.0% (CI, 10.2-17.9%) per year for chronic lymphocytic leukemia, by 5.1% (CI, 3.1-7.2%) for non-Hodgkin lymphoma and by 3.2% (CI, 0.3-6.1%) per year for multiple myeloma. Surveillance of mortality based on MCOD is warranted to accurately measure the impact of the COVID-19 pandemic and of other epidemics, including seasonal flu, on patients with hematologic malignancies, and to assess the effects of vaccination campaigns and other preventive measures.
Participants will alternate between wearing the Quick-Set Teflon catheter for 7 days, then the Quick-Set Teflon for 7 days. They will wear each set twice starting with the Quick-Set Teflon set.
Study subjects will complete up to eight additional neuropsychological assessments, intermittently separated followed by the Cognivue Plus test. Next, study participants assigned to this group will complete the Cognivue 5-Minute Screening test across three domains including Memory, Visuospatial and Executive Function as well as two performance measures of Reaction Time and Speed Processing along with Normative Ranges 3 times OR study participants assigned to this group will complete the Cognivue 10-Minute Assessment test across six domains including Memory, Visuospatial, Executive Function, Naming/Language, Memory, Delayed Recall and Abstraction, as well as two performance measures of Reaction Time and Speed Processing, along with Normative Ranges 3 times.
The present invention provides an extraction method of salvianolic acid B. The method comprises the following steps: (1) salvia miltiorrhiza is extracted once to four times by  30 percent to 60 percent of ethanol solution; the extracted solution is mixed; the ethanol is recycled until the solution has no taste of alcohol; the deposits are separated from the extracted solution without the ethanol so as to prepare the filtrate; (2) macropores in the filtrate are used for absorbing resin; distilled water is used for eluting until eluent is clarified; then 20 to 50 percent of ethanol solution is used for eluting; the ethanol eluent is collected; and (3) the ethanol eluent is concentrated and dried at the temperature between 40 DEG C and 70 DEG C, so as to prepare the powder of the salvianolic acid B. The extraction method has the main beneficial effects of simple process, more reasonable technical parameters, easy operation and low cost. The content of the salvianolic acid B in the power reaches to more than 60 percent and the yield rate reaches to more than 3 percent; the medical material of salvia miltiorrhiza is effectively applied. The powder of the extracted salvianolic acid B can be used for preparing capsules, tablets and other solid preparations through a simple process, after adding a plurality of ordinary supplementary materials. And the extraction method is suitable for large-scale industrial production.
A computer-implemented method is disclosed. The method includes determining whether one or more messages have been received from at least one of an electromechanical machine, a sensor, and an interface. Then the one or more messages may pertain to at least one of a user and a usage of the electromechanical machine by the user. The electromechanical machine may be configured to be manipulated by the user while the user is performing a treatment plan. The method also includes, responsive to determining that the one or more messages have not been received, determining, using one or more machine learning models, one or more preventative actions to perform. The method also includes causing the one or more preventative actions to be performed.
Excessive hypotension was rarely seen (0.1%) in patients with uncomplicated hypertension treated with valsartan alone. In patients with an activated renin-angiotensin system, such as volume- and/or salt-depleted patients receiving high doses of diuretics, symptomatic hypotension may occur. This condition should be corrected prior to administration of valsartan, or the treatment should start under close medical supervision.   
  
Patients with heart failure or post-myocardial infarction patients given valsartan commonly have some reduction in blood pressure, but discontinuation of therapy because of continuing symptomatic hypotension usually is not necessary when dosing instructions are followed. In controlled trials in heart failure patients, the incidence of hypotension in valsartan-treated patients was 5.5% compared to 1.8% in placebo-treated patients. In the VALsartan In Acute myocardial iNfarcTion trial (VALIANT), hypotension in post-myocardial infarction patients led to permanent discontinuation of therapy in 1.4% of valsartan-treated patients and 0.8% of captopril-treated patients.   
  
If excessive hypotension occurs, place the patient in the supine position and, if necessary, give intravenous normal saline. A transient hypotensive response is not a contraindication to further treatment, which usually can be continued without difficulty once the blood pressure has stabilized.
Pathological cardiac hypertrophy is one of the major risk factors of heart failure and other cardiovascular diseases. However, the mechanisms underlying pathological cardiac hypertrophy remain largely unknown. Here, we identified the first evidence that TNFAIP3 interacting protein 3 (TNIP3) was a negative regulator of pathological cardiac hypertrophy. We observed a significant upregulation of TNIP3 in mouse hearts subjected to transverse aortic constriction (TAC) surgery and in primary neonatal rat cardiomyocytes stimulated by phenylephrine (PE). In Tnip3-deficient mice, cardiac hypertrophy was aggravated after TAC surgery. Conversely, cardiac-specific Tnip3 transgenic (TG) mice showed a notable reversal of the same phenotype. Accordingly, TNIP3 alleviated PE-induced cardiomyocyte enlargement in vitro. Mechanistically, RNA-sequencing and interactome analysis were combined to identify the signal transducer and activator of transcription 1 (STAT1) as a potential target to clarify the molecular mechanism of TNIP3 in pathological cardiac hypertrophy. Via immunoprecipitation and Glutathione S-transferase assay, we found that TNIP3 could interact with STAT1 directly and suppress its degradation by suppressing K48-type ubiquitination in response to hypertrophic stimulation. Remarkably, preservation effect of TNIP3 on cardiac hypertrophy was blocked by STAT1 inhibitor Fludaradbine or STAT1 knockdown. Our study found that TNIP3 serves as a novel suppressor of pathological cardiac hypertrophy by promoting STAT1 stability, which suggests that TNIP3 could be a promising therapeutic target of pathological cardiac hypertrophy and heart failure.
PURPOSE:An agent against mutagenesis for deactivating mutagenesis of carcinostatic substance, containing phyridoxal-5'-phosphate, a vitamin B complex component of type present in vivo, as an active ingredient. CONSTITUTION:An agent against mutagenesis containing pyridoxal phosphate such as a compound shown by the formula I as an active ingredient. The compound shown by the formula I inhibits about 50wt% mutagenesis of N-methyl-N'- nitro-N-nitroguanidine, a carcinogenic substance in the stomach and the intestine when 150 times as much the compound shown by the formula I as the nitroguanidine by molar amount is used. It deactivates about 80wt% benz [a]pyrene a carcinogenic substance in the liver and the skin, when 25 times as much the compound as benz [a]pyrene by molar amount is used. Namely, pyridoxal-5'- phosphate is found to be effective for preventing carcinogenesis as an agent for mutagenesis. Vitamin B6 shown by the formula II is a type present in vivo, safe, has effects as vitamin, and is usable in the field of drug, food, or table luxuries.
PCT No. PCT/US94/07770 Sec. 371 Date Jan. 11, 1996 Sec. 102(e) Date Jan. 11, 1996 PCT Filed Jul. 8, 1994 PCT Pub. No. WO95/02069 PCT Pub. Date Jan. 19, 1995Compositions and methods are provided for the treatment and diagnosis of diseases associated with protein kinase C. Oligonucleotides are provided which are specifically hybridizable with a PKC gene or mRNA. Oligonucleotides specifically hybridizable with a particular PKC isozyme, set of isozymes or mRNA transcript are provided. Methods of treating conditions amenable to therapeutic intervention by modulating protein kinase C expression with an oligonucleotide specifically hybridizable with a PKC gene or mRNA are disclosed. Compositions and methods are provided for the treatment, detection and diagnosis of diseases associated with protein kinase C alpha and specific transcripts thereof. New nucleic acid sequences are provided which encode 3' untranslated regions of human protein kinase C alpha polynucleotide probes for PKC alpha are also disclosed.
The mammalian placenta's interface with the parent is a richly vascularized tissue whose development relies upon communication between many different cell types within the uterine microenvironment. The uterine blood vessels of the interface are reshaped during pregnancy into wide-bore, flaccid vessels that convey parental blood to the exchange region of the placenta. Invasive trophoblast as well as parental uterine macrophages and Natural Killer cells are involved in the stepwise remodeling of these vessels and their respective contributions to this crucial process are still being delineated. However, the earliest steps in arteriole remodeling are understudied as they are difficult to study in humans, and other species lack the deep trophoblast invasion that is so prominent a feature of placentation in humans. Here, we further characterize the rat, with deep hemochorial placentation akin to humans, as a model system in which to tease apart the earliest, relatively understudied events in spiral arteriole remodeling. We show that the rat uterine-placental interface increases in size and vascularity rapidly, before trophoblast invasion. The remodeling stages in the arterioles of the rat uterine-placental interface follow a sequence of anatomical changes similar to those in humans, and there are changes to the arterioles' muscular tunica media prior to the marked influx of immune cells. The rat is a tractable model in which to better understand the cell/cell interactions occurring in vivo in an intact tissue microenvironment over time.
OBJECTIVES: I. Determine the effect of weekly doxorubicin on the quality of life of patients with metastatic, hormone-refractory, symptomatic prostate cancer. II. Determine the contribution of this treatment on control of pain in these patients. III. Determine the toxicity of this regimen in these patients. IV. Determine the objective response and biological observations in these patients after this treatment. V. Determine the effect of this regimen on survival of these patients.

OUTLINE: This is a randomized, multicenter study. Patients are randomized to one of two treatment arms. Arm I: Patients receive methylprednisolone IV weekly for 3 months. Arm II: Patients receive methylprednisolone IV and doxorubicin IV weekly for 3 months. Quality of life is assessed before treatment, every 4 weeks during treatment, and then every 3 months. Patients are followed every 3 months.

PROJECTED ACCRUAL: A total of 160 patients will be accrued for this study within 3 years.
The invention relates to ciclesonide nanoparticle aqueous solution and a preparation method thereof, belonging to the technical field of medicinal preparation. The ciclesonide nanoparticle aqueous solution comprises the following ingredients: ciclesonide, a carrier material and a surfactant. The preparation method of the ciclesonide nanoparticle aqueous solution comprises the following steps: adding the ciclesonide and the carrier material in an organic solvent, dissolving to obtain organic phase solution; adding the surfactant into water, dissolving to obtain aqueous phase solution; mixing the organic phase solution and the aqueous phase solution, stirring to obtain emulsion, distilling, and removing the organic solvent in the system to obtain the ciclesonide nanoparticle aqueous solution. The invention has the advantages that the ciclesonide nanoparticle aqueous solution is stable in system, large in dispersity and high in bioavailability. The average particle diameter of the nanoparticle aqueous solution is less than 400 nanometers, the polydispersity index is less than 0.5, and the medicament encapsulation efficiency is more than 80 percent. Furthermore, the method is simple in technique processes and beneficial to industrial production.
A compound of Formula (I) or a pharmaceutically acceptable salt or prodrug thereof, wherein C is a compound of Formula (II): Wherein L1 and L2 are linkers; T is a targetting moeity; a is 1-5; b is 1-10; z is 1-5; X1-3 is CR1-3 respectively or N; Q is C=O, S=O, SO2 or CR4R5; Y and L are as herein defined; R1-11 arer as herein defined. T may comprise an antibody, an antibody fragment, a nucleic acid based molecule, a carbohydrate, an optionally modified peptide or small molecule. T may be configured to target a tumour antigen. Compounds of formula (I) are conjugates of small molecule modulators of the Stimulator of Interferon Genes (STING) protein and may be used to treat diseases such as cancer and microbial infections. Pharmaceutical compositions comprising a compound of Formula (I) are also disclosed. Compounds of Formula (III); (C-L1)-L2a are also disclosed wherein such compounds are suitable for preparing a compound of Formula (I), wherein C and L1 are as defined above, and L2a is L2-LG wherein LG is a leaving group, or L2 as define above, except that the linker comprises a terminal double bond.
This study investigates the reading performance of younger students with intellectual disabilities to gain insight into their needs in reading education. Participants were 428 students in Grades 1 to 3 in Sweden. They performed LegiLexi tests measuring pre-reading skills, decoding and reading comprehension based on the model of Simple View of Reading. Results demonstrate a great variation in reading acquisition among students. Some students are able to decode single words and read shorter texts with comprehension already in Grade 1. Other students still struggle with learning letters and developing phonological awareness in Grade 3. According to their longitudinal data over grades, results show that most students progress in pre-reading skills, decoding, and reading comprehension. Hence, assessing reading skills among students with intellectual disabilities in Grades 1-3 using tools aligned with the Simple View of Reading seems applicable and informative for teachers. This study underscores the significance of informed instructional practices for empowering these students in reading education.
<P>PROBLEM TO BE SOLVED: To further optimize levels of transgene expression.  <P>SOLUTION: There are provided improved genetic elements providing high levels of expression of operably-linked genes in a variety of tissues. In particular, fragments of unmethylated CpG islands of less than 2 kb are shown to provide enhanced transgene expression and have advantages in terms of vector construction and cloning capacity. There is provided a polynucleotide comprising a smaller ubiquitous chromatin opening elements (UCOE). The element provides a gene expression of high levels and reproducibility, when operably-linked to an expressible nucleic acid sequence.  <P>COPYRIGHT: (C)2010,JPO&INPIT
Many people with SCI experience neuropathic pain. Neuropathic pain is often described as sharp, burning, or electric. 'Traditional' treatments often do not do a good job of reducing neuropathic pain. Therefore, it is important to see if 'non-traditional' treatments might work. Scientists think that neuropathic pain occurs in SCI because the sensations coming from the eyes and up the spinal cord to the brain do not match what the brain thinks it told the body to do. This 'mis-match' may result in changes in the brain that make neuropathic pain possible. Virtual reality walking reduces this 'mis-match.' It does this by creating the 'illusion' that the person is walking. The brain then thinks it is telling the body to walk AND the information coming from the eyes matches its instructions. This 'matching' may reverse the brain changes that made neuropathic pain possible. The current study is specifically focused on individuals whose SCI has been classified as complete (ASIA A).
BACKGROUND: In the health system, hospitals are intricate establishments that offer vital medical services. Their resilience plays a crucial role in mitigating the societal repercussions of disasters. A hospital must possess the capacity to withstand risks, preserve its fundamental structure and operations, and enhance its preparedness by augmenting various capabilities and promptly recovering from the impacts of potential risks. It enables the hospital to attain a heightened level of readiness. Therefore, this study aimed to develop a resilience model tailored for hospitals to navigate crises and disasters effectively.
METHODS: This mixed-method study was conducted in 2023 in three phases: (1) Identification of the factors influencing the organizational resilience of the hospital, (2) Evaluation of the influential factors by an expert panel. (3) Following the standardization process, we administered 371 questionnaires to individuals, such as university staff managers and supervisors, nursing managers, and research unit managers. The sample size was determined by multiplying the components by 10, resulting in 360 (10 * 36). Therefore, we selected a sample size of 371 participants. Structural Equation Modeling (SEM) was employed to examine the causal relationships between variables. These steps were performed using SPSS 25.0 and AMOS 22 software. Finally, we identified and presented the final model. We utilized AMOS 22 and applied the SEM to assess the correlation between the variables, with a significance level of 0.05.
RESULTS: Findings indicate that the appropriate modeling identified five dimensions comprising 36 components. These dimensions include vulnerability, preparedness, support management, responsiveness and adaptability, and recovery after the disaster. The model demonstrates a good fit, as indicated by the X2/d indices with a value of 2.202, a goodness of fit index (GFI) of 0.832, a root mean square error of estimation (RMSEA) of 0.057, an adjusted comparative fit index (CFI) of 0.931, and a smoothed fit index (NFI) of 0.901.
CONCLUSION: Enhancing hospital resilience is crucial for effective preparedness and response to accidents and disasters. Developing a localized tool for measuring resilience can help identify vulnerabilities, ensure service continuity, and inform rehabilitation programs. The proposed model is a suitable framework for assessing hospital resilience. Key factors include human resource scarcity, hospital specialization, and trauma center capacity. Hospitals should prioritize efficient resource allocation, information technology infrastructure, in-service training, waste management, and a proactive organizational framework to build resilience. By adopting this approach, hospitals can better respond to crises and disasters, ultimately reducing casualties and improving overall preparedness.